TY  - CHAP
M1  - Book, Section
TI  - Mood Disorders
A1  - Valentine, Alan D.
A2  - Duffy, James D.
A2  - Valentine, Alan D.
Y1  - 2016
N1  - 
T2  - MD Anderson Manual of Psychosocial Oncology
AB  - Depression  in  the  general  population  is  a  major  public  health  problem,  its  most  severe  form  (major  depression  [MDD])  affecting  almost  7%  of  American  adults.1  Depressive  spectrum  disorders  are  sufficiently  common  in  oncology  that  clinicians  of  all  specialties  working  in  the  field  can  expect  to  encounter  patients  with  presentation  of  these  states  on  a  daily  basis.  Because  of  the  negative  emotional  valence  associated  with  cancer,  depression  may  be  overlooked  or  ignored  as  a  "normal"  consequence  of  the  cancer  experience,  not  requiring  or  unlikely  to  respond  to  treatment  (therapeutic  nihilism).2  Depressive  disorders  adversely  affect  quality  of  life  and  appear  to  increase  medical  morbidity  and  symptom  burden  in  cancer  patients.3,4,5  Depression  predicts  desire  for  hastened  death  in  terminally  ill  patients,  as  does  hopelessness.6  There  is  increasing  evidence  that  depression  predicts  early  mortality  from  malignancy,  although  some  studies  have  not  found  this  to  be  the  case.7,8,9,10,11,12  Familiarity  with  differential  diagnosis  and  treatment  options  for  depressive  disorders  is  an  essential  component  of  comprehensive  care  and  can  do  much  to  palliate  emotional  distress  of  patients  and  caregivers.  Diagnosis  and  treatment  of  mood  disorders  can  be  time  intensive  and  thus  potentially  problematic  for  clinicians  with  busy  practices  or  with  understandable  preoccupation  with  therapeutic  decisions  or  focus  on  more  acute  symptoms  (ie,  pain,  dyspnea).  However,  to  the  extent  that  depressive  states  interfere  with  or  complicate  treatment,  identification  and  treatment  of  symptoms  could  also  make  care  more  efficient  and,  possibly,  less  stressful  for  clinicians.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - hemonc.mhmedical.com/content.aspx?aid=1125785106
ER  -